Join the club for FREE to access the whole archive and other member benefits.

Longevity Technology interviews cellvie CEO, Alex Schueller, about therapeutic mitochondria

14-Sep-2022

Key points from article :

The founders of cellvie wondered if it were possible to replace and augment damaged mitochondria.

Have raised $5 million in Kizoo-led seed funding.

Therapeutic Mitochondria Transplantation (TMT) holds the potential of sustainably affecting mitochondria function.

Want to establish off-the-shelf mitochondria that can be frozen, then thawed for immediate use by the physician.

Looking at where therapeutic mitochondria can intersect with age-related degeneration.

Ischemia-reperfusion injury is its frontrunner indication which has a timelier endpoint than ageing.

Can then develop, longer-term, aging-related applications.

Initially targeting ischemia-reperfusion injury, TMT has potential to treat multiple age-related diseases

Mentioned in this article:

Click on resource name for more details.

Alex Schueller

Founder and CEO at Cellvie

Cellvie

Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell

KIZOO Technology Ventures

Company providing financing and its focus is on rejuvenation biotech